Abstract
In this work a new coupling reagent, N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, for radiohalogenation has been synthesized and characterized. The reagent is intended to either be attached to reduced disulfide bridges of proteins (making the halogenation site-specific) or to free terminal cysteine groups on peptides. The new reagent was also shown to be easily halogenated with inactive bromine and iodine as well as (125)I and (211)At, indicating potential use within targeted radiotherapy.
Keywords:
Astatine-211; Electrophilic aromatic substitution; Halogenation; Peptide labelling; Site specific antibody labelling; Targeted radiotherapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Astatine / chemistry
-
Astatine / therapeutic use
-
Benzamides / chemical synthesis
-
Benzamides / chemistry*
-
Bromine / chemistry
-
Chromatography, High Pressure Liquid
-
Halogenation*
-
Humans
-
Indicators and Reagents
-
Iodine Radioisotopes / chemistry
-
Iodine Radioisotopes / therapeutic use
-
Molecular Structure
-
Organotin Compounds* / chemistry
-
Peptides / chemistry
-
Peptides / therapeutic use
-
Proteins / chemistry
-
Proteins / therapeutic use
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / chemistry
-
Radiopharmaceuticals / therapeutic use
Substances
-
Benzamides
-
Indicators and Reagents
-
Iodine Radioisotopes
-
N-(2-(maleimido)ethyl)-3-(trimethylstannyl)benzamide
-
Organotin Compounds
-
Peptides
-
Proteins
-
Radiopharmaceuticals
-
Bromine
-
Astatine